度洛西汀治疗恶性肿瘤患者伴发抑郁障碍分析

目的探讨度洛西汀对恶性肿瘤患者伴发抑郁障碍的临床疗效及安全性。方法60例肿瘤伴发抑郁的患者，随机分为两组，每组30例，两组患者均接受常规抗肿瘤治疗，研究组在此基础上联合度洛西汀治疗，观察8周。于治疗前及治疗2周、4周及8周末采用汉密尔顿抑郁量表评定抑郁情绪，副反应量表评定不良反应。结果治疗8周末研究组抑郁情绪改善率为76．7％，未治疗组为26．7％，研究组显著高于未治疗组（P〈O．01）；研究组汉密尔顿量表评分较未治疗组显著下降（P〈O．05）；两组不良反应无差异性。结论度洛西汀治疗肿瘤患者伴发抑郁障碍效果显著，安全性高。

A study of duloxetine in the trentment of tumor patients with depression disorders.

Objective To explore the clinical efficacy and safety of duloxetine in treatment of tumor patients with depression disorders. Methods 60 patients were randomly divided into groups of 30 ones each to one group was plused duloxetine for 8 weeks. Depressive emotions were assessed with the Hamilton Depression Rating Scale （HAMD） and adverse reactions with Treatment Emergent Symptom Scale （TESS） before treatment and at the the 2nd, 4th and 8th week. Results Improvement rates of depression emotion were respectively 76. 7% in the research and 26. 7% in the no duloxetire group at the end of 8th week, the former were significantly higher than the latter （ P 〈0. 01 ）, scores of both the HAMD lowered more sighiticantly in the research than in the no duloxetine group （P〈 0. 05）. Adverse reactions of the two groups were not different. Conclusion Duloxetine has a notable effect and high safety in the treatment of patients with depression disorders, can improves patients＇ quality of life significantly.